Edition:
United States

T2 Biosystems Inc (TTOO.OQ)

TTOO.OQ on NASDAQ Stock Exchange Global Market

6.45USD
17 Aug 2018
Change (% chg)

$-0.04 (-0.62%)
Prev Close
$6.49
Open
$6.45
Day's High
$6.56
Day's Low
$6.30
Volume
98,464
Avg. Vol
198,568
52-wk High
$9.98
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

T2 Biosystems Q4 Revenue Rose 55 Percent To $1.7 Million
Tuesday, 6 Mar 2018 04:00pm EST 

March 6 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND BUSINESS UPDATE.SEES Q1 2018 REVENUE $1.3 MILLION TO $1.6 MILLION.Q4 REVENUE ROSE 55 PERCENT TO $1.7 MILLION.Q1 2018 PRODUCT REVENUE IS EXPECTED TO BE IN RANGE OF $0.9 MILLION TO $1.1 MILLION.COMPANY EXPECTS TO CLOSE AT LEAST 6 NEW CONTRACTS IN Q1 2018.  Full Article

T2 Biosystems Says John Sprague Has Been Named CFO
Monday, 5 Feb 2018 04:30pm EST 

Feb 5 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS ANNOUNCES CFO TRANSITION.T2 BIOSYSTEMS INC - JOHN SPRAGUE HAS BEEN NAMED CHIEF FINANCIAL OFFICER.  Full Article

T2 Biosystems CFO Darlene Deptula-Hicks Resigns
Monday, 5 Feb 2018 04:10pm EST 

Feb 5 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS- ON JAN 30, DARLENE DEPTULA-HICKS NOTIFIED CO OF HER RESIGNATION FROM POSITION AS CO'S CHIEF FINANCIAL OFFICER EFFECTIVE IMMEDIATELY.T2 BIOSYSTEMS- ANTICIPATES ENTERING INTO SEPARATION AGREEMENT WITH DEPTULA-HICKS PURSUANT TO WHICH SHE WILL EXECUTE GENERAL RELEASE OF CLAIMS IN CO'S FAVOR.T2 BIOSYSTEMS SAYS ‍APPOINTED JOHN M. SPRAGUE TO SERVE AS CO'S CHIEF FINANCIAL OFFICER ON JAN 30 - SEC FILING​.  Full Article

T2 Biosystems Says ‍Total Q4 Revenue Is Expected To Exceed Previously Guided Range Of $1.1 Mln To $1.3 Mln​
Thursday, 4 Jan 2018 04:05pm EST 

Jan 4 (Reuters) - T2 Biosystems Inc ::T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON T2BACTERIA PANEL.- ‍FDA CLEARANCE OF T2BACTERIA PANEL REMAINS ON TRACK FOR Q1 2018​.‍TOTAL REVENUE IN Q4 IS EXPECTED TO EXCEED PREVIOUSLY GUIDED RANGE OF $1.1 TO $1.3 MILLION​.  Full Article

T2 Biosystems Q3 loss per share $0.45
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - T2 Biosystems Inc :T2 biosystems reports third quarter 2017 financial results and provides company update.Q3 loss per share $0.45.Sees q4 revenue $1.1 million to $1.3 million.Q3 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Q3 revenue $1.1 million versus i/b/e/s view $1.1 million.T2 biosystems inc - ‍company reaffirms expectations regarding timeframe for fda clearance of t2bacteria panel​.T2 biosystems inc - ‍continues to prepare for commercial launch of t2bacteria panel in u.s. As early as year-end, pending market clearance by fda.​.T2 biosystems inc - ‍cash and cash equivalents as of sept 30 with additional remaining liquidity on term loan , should extend cash runway into h1 2019​.  Full Article

T2 Biosystems announces pricing of public offering of common stock
Friday, 15 Sep 2017 08:20am EDT 

Sept 15 (Reuters) - T2 Biosystems Inc :T2 Biosystems announces pricing of public offering of common stock.Says public offering of 4.38 million common shares priced at $4 per share.  Full Article

T2 Biosystems announces proposed public offering of common stock
Thursday, 14 Sep 2017 04:11pm EDT 

Sept 15 (Reuters) - T2 Biosystems Inc :T2 Biosystems announces proposed public offering of common stock.  Full Article

T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel
Monday, 11 Sep 2017 08:00am EDT 

Sept 11 (Reuters) - T2 Biosystems Inc :T2 Biosystems submits 510(K) application to the FDA for review of T2Bacteria Panel‍​.  Full Article

T2 Biosystems, Cidara Therapeutics enter partnership for commercial placement of T2Dx instruments
Wednesday, 6 Sep 2017 11:05am EDT 

Sept 6 (Reuters) - T2 Biosystems::Co, Cidara Therapeutics entered into exclusive partnership for commercial placement of T2Dx instruments to support CD101 drug trials​.Program is designed to accelerate enrollment in Cidara's CD101 trials and to increase uptake of T2's products..  Full Article

T2 Biosystems to collaborate with CDC to detect emerging superbug Candida Auris​
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - T2 Biosystems Inc :T2 Biosystems Inc - ‍announces collaboration with CDC to detect emerging superbug Candida Auris​.  Full Article

BRIEF-T2 Biosystems Amends Oct. 10, 2014 Supply Agreement With SMC Ltd

* T2 BIOSYSTEMS SAYS ON MAY 16, CO & SMC LTD ENTERED INTO A THIRD AMENDMENT AMENDING CERTAIN SUPPLY AGREEMENT DATED AS OF OCT. 10, 2014 - SEC FILING